Table 1.

Dosimetric comparison (target coverage) of 30 patients that were planned by: PRO using the manual objectives as in the clinical plans (clinical); PO using the RapidPlan‐generated objectives (PO); and PRO using the RapidPlan‐generated objectives (PRO). Dose unit (Gy)

		Mean	SD	95% Confidence interval		P
				Lower	Upper
DPTVboost	Clinical	52.22	0.19	52.15	52.29	<0.01a
	PO	51.93	0.23	51.85	52.01	0.03a
	PRO	52.05	0.30	51.94	52.16
DPTV	Clinical	45.51	0.79	45.22	45.81	<0.01
	PO	45.85	0.75	45.57	46.13	0.19
	PRO	45.94	0.72	45.67	46.21
HIPTVboost	Clinical	0.06	0.01	0.06	0.06	<0.01
	PO	0.05	0.01	0.05	0.05	0.53
	PRO	0.05	0.01	0.04	0.05
HIPTV	Clinical	0.26	0.01	0.26	0.26	<0.01
	PO	0.25	0.01	0.25	0.26	<0.01
	PRO	0.26	0.01	0.26	0.26
CIPTVboost	Clinical	1.01	0.03	1.00	1.02	<0.01a
	PO	1.06	0.05	1.05	1.08	0.60a
	PRO	1.07	0.05	1.05	1.09
CIPTV	Clinical	1.04	0.03	1.03	1.05	0.34
	PO	1.05	0.03	1.04	1.06	<0.01a
	PRO	1.03	0.03	1.02	1.04
MUs	Clinical	404	30	392	415	<0.01
	PO	436	33	423	448	0.81
	PRO	437	29	426	448

^aWilcoxon signed‐rank test (abnormal distribution); otherwise paired samples t‐test (normal distribution).

D_PTVboost, mean dose to PTV_boost; D_PTV, mean dose to PTV; HI, homogeneity index; CI, conformity index; SD, standard deviation; and MUs, monitor units.